WEBULL
WebtradeDownload

Shionogi (TSE:4507) Starts U.S. XOCOVA Sales As Strong Q1 Results Put Valuation In Focus

Simply Wall St · 2d ago

Shionogi (TSE:4507) has just posted first quarter results that show higher sales and net income compared with a year earlier, and it has also begun United States sales of its FDA approved COVID-19 post exposure prophylaxis drug XOCOVA.

See our latest analysis for Shionogi.

The recent launch of XOCOVA in the U.S. and strong first quarter figures have not yet translated into sustained share price strength. Shionogi’s 90 day share price return is down 11.06% and its year to date share price return is down 1.38%, even as its 1 year total shareholder return sits at 10.28% and its 3 year total shareholder return at 45.77%. This points to longer term investors still being ahead despite recent momentum fading.

If you are looking beyond Shionogi and want to see which other health related companies are linked to AI trends, the 7 healthcare AI stocks can be a useful starting point.

Bulls point to Shionogi’s jump in quarterly earnings and the new XOCOVA opportunity in the U.S., while bears focus on recent share price weakness. Which side does the current valuation evidence lean toward as you weigh the stock today?

Price-to-Earnings of 9.1x for Shionogi: Is it justified?

On a simple snapshot, Shionogi is trading on a P/E of 9.1x, while the stock screens as good value against peers, the wider JP Pharmaceuticals industry, and an estimated fair ratio.

The P/E multiple compares the current share price to earnings per share. It effectively shows how much investors are paying today for each unit of Shionogi’s earnings, which is a common way to benchmark established pharmaceutical companies.

For Shionogi, the current P/E of 9.1x is described as good value compared with the peer average of 18.3x and the JP Pharmaceuticals industry average of 15.3x. It is also flagged as attractive versus an estimated fair P/E of 21.2x, which is the level the multiple could trend toward if the market assigned a valuation in line with those relationships.

Put simply, Shionogi’s earnings are currently priced at a clear discount to both industry norms and this fair ratio benchmark, which suggests the current P/E leaves some room if the market revisits those levels.

Explore the SWS fair ratio for Shionogi

Result: Price-to-Earnings of 9.1x (UNDERVALUED)

However, Shionogi still faces risks if XOCOVA uptake in the U.S. is slower than investors expect or if revenue growth and net income trends remain mixed.

Find out about the key risks to this Shionogi narrative.

Another view on Shionogi’s value using cash flows

While Shionogi looks inexpensive on a 9.1x P/E, the SWS DCF model also values the stock at ¥6,208.2 per share based on estimated future cash flows compared with today’s ¥2,825.5 price. That is a large gap. Could the cash flow view be too optimistic, or is the market too cautious?

Look into how the SWS DCF model arrives at its fair value.

4507 Discounted Cash Flow as at Aug 2026
4507 Discounted Cash Flow as at Aug 2026

Simply Wall St performs a discounted cash flow (DCF) on every stock in the world every day (check out Shionogi for example). We show the entire calculation in full. You can track the result in your watchlist or portfolio and be alerted when this changes, or use our stock screener to discover 18 high quality undervalued stocks. If you save a screener we even alert you when new companies match - so you never miss a potential opportunity.

Next Steps

Does the mixed mood around Shionogi leave you curious rather than convinced? Act while the data is fresh and review both sides of the story using the 5 key rewards and 2 important warning signs.

Looking for more investment ideas beyond Shionogi?

If Shionogi has you thinking more broadly about opportunities, use this momentum and scan for other stocks that fit clear, data backed criteria.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.